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Abstract
Several papers published in the last 2-3 years suggest that transient receptor potential vanilloid
4 (TRPV4) channels are candidates as mechanosensors in the urinary bladder (including human) and
indicate that modulation (inhibition) of these channels could represent a novel therapy for overactive
bladder and storage dysfunction. The effects of only agonists on the bladder have been described up
to now, although some compounds endowed with antagonistic activity were reported in the last year.
Therefore, it is to be hoped that the effects of these compounds in different models of bladder
overactivity will be evaluated.
Introduction and context
Transient receptor potential vanilloid 4 (TRPV4), a
member of the TRP superfamily of cation channels, is
aC a
2+-permeable channel. The TRPV family contains
six mammalian members: TRPV1 to TRPV6. TRPV1 to
TRPV4 are all heat-activated channels that are nonselec-
tive for cations and modestly permeable to Ca
2+, with
permeability ratios (PCa/PNa) of between about 1 and
10. In addition, TRPV1 to TRPV4 function as chemo-
sensors for a broad array of endogenous and synthetic
ligands. The properties of the two other members of this
subfamily, TRPV5 and TRPV6, are quite different from
those of TRPV1 to TRPV4. They are the only highly Ca
2+-
selective channels in the TRP family, and both are tightly
regulated by the intracellular calcium ion concentration
([Ca
2+]i) ([1] and references therein).
With regard to TRPV4, this channel is activated by a wide
variety of physical and chemical stimuli [1,2]. The
activation of TRPV4 may be induced by hypotonic
stimuli in response to hypotonicity-induced cell swelling
[3-5] and shear stress [6]. Alternatively, TRPV4 can be
activated by diverse chemical stimuli such as the
synthetic phorbol ester 4a-PDD (4a-phorbol 12,13
didecanoate), anandamide metabolites such as arachi-
donic acid and epoxyeicosatrienoic acids, and moderate
warmth (>27°C) [7-10].
TRPV4 is widely expressed throughout the body, includ-
ing renal epithelium, auditory hair cells, skin keratino-
cytes, hippocampus neurons, endothelial cells, and
urinary bladder epithelium, thereby contributing to
numerous physiological processes such as osmoregula-
tion, hearing, thermal and mechanical hyperalgesia,
neural activity in the brain, skin barrier recovery, and
cell volume regulation. Therefore, the TRPV4 channel is
now considered a multimodal transducer in various
tissues and cells [11,12].
The role of TRPV4 channels in bladder function was first
reported by Gevaert et al. [13]. These authors demon-
strated that TRPV4 was expressed mainly in bladder basal
and intermediate urothelial cells and functioned as a
Ca
2+ influx pathway activated by hypotonic cell swelling
and induced by the specific TRPV4 agonist 4a-PDD
(Figure 1) in these cells. Furthermore, they found that
mice lacking TRPV4 displayed a severely disturbed urine-
voiding pattern. Cystometry experiments revealed that
TRPV4 knockout mice exhibited a lower frequency of
voiding contractions as well as a higher frequency of
nonvoiding contractions. No significant differences in
amplitude or duration of both voiding and nonvoiding
contractions were found. The total amount of urine per
cystometry-induced voiding episode was greater in
TRPV4 knockout mice in comparison with wild-type
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lower amplitude of spontaneous contractions and a
decrease in stretch-evoked intravesical ATP release in
bladders from TRPV4 knockout mice.
Birder et al. [14] confirmed that rat urothelial cells also
express functional TRPV4 channels since TRPV4 mRNA
and protein are both detectable. The exposure of these
cells to the selective TRPV4 agonists 4a-PDD and
5
0,6
0-EET (5
0,6
0-epoxyeicosatrienoic acid) (Figure 1)
induced Ca
2+ influx and ATP release, both of which
can be blocked by the antagonist ruthenium red.
Furthermore, the hypo-osmolarity-evoked ATP release
from urothelial cells is potentiated by 4a-PDD, and 4a-
PDD-evoked [Ca
2+]i responses are inhibited by hyper-
osmolarity. It is also reported that during continuous
infusion cystometrograms in awake rats, intravesical
administration of 4a-PDD increased maximal micturi-
tion pressure, specifically by augmenting the portion of
each intravesical pressure wave that follows high-
frequency urethral oscillations and voiding. This effect
was prevented by intravesical pretreatment with a
nonselective ATP receptor antagonist or systemic treat-
ment with a selective P2X3 purinergic antagonist or
urethane anesthesia but was unaffected by capsaicin
pretreatment or denervation of the urethral sphincter.
4a-PDD, however, did not alter the contractility to
electrical stimulation of excised bladder strips.
By using a novel TRPV4 channel activator
(GSK1016790A) (Figure 1) that is about 300-fold more
potentthanthecommonlyusedTRPV4activator4a-PDD,
Thorneloe et al. [15] showed that this compound elicited
Ca
2+ influx in mouse and human TRPV4-expressing
Figure 1. Chemical structures of selected transient receptor potential vanilloid 4 (TRPV4) agonists and of the TRPV4 antagonist RN-1734
The general formula of antagonists described in the patent WO/2009/11680 [30] is also shown. 4a-PDD, 4a-phorbol 12,13 didecanoate; 5
0,6
0-EET,
5
0,6
0-epoxyeicosatrienoic acid; APP441-1, 4a-phorbol-diesanoate; GSK1016790A, (N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxy-
propanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide; RN-1734, 2,4-dichloro-N-isopropyl-N-[2-(isopropylamino)
ethyl]benzenesulfonamide.
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dose-dependent activation of TRPV4 whole-cell currents.
In the same paper, it is reported that TRPV4 mRNA was
detected in urinary bladder smooth muscle and urothe-
lium of mouse bladders but was absent in TRPV4
knockout bladders. Accordingly, TRPV4 activation with
GSK1016790A contracted wild-type mouse bladders
in vitro, an effect that was undetected in TRPV4 knockout
bladders. In vivo, cystometry performed in conscious mice
revealed an enhanced bladder capacity in the TRPV4
knockoutanimals,andinfusionofGSK1016790Aintothe
bladders of normal mice induced bladder overactivity
with no effect in TRPV4 knockout animals.
Major recent advances
In a more recent study, Yamada et al. [16] morphologi-
cally confirmed by immunoblotting and immunohisto-
chemical studies that TRPV4 (but not TRPV1) channels
were expressed in mouse urothelial cells, especially at the
basal plasma membrane domains of the basal urothelial
cells, and that the isolated urothelial cells showed
marked increases in [Ca
2+]i when 4a-PDD and hypo-
tonic stimuli were applied. Similarly, Xu et al. [17]
showed that the TRPV1 agonist capsaicin, which
activated TRPV1 currents in HEK cells expressing
TRPV1, was unable to evoke current in freshly isolated
guinea pig urothelial cells, and other authors [18]
demonstrated that 4a-PDD elicited transient currents
in a high percentage of cultured rat urothelial cells
(>70%) whereas capsaicin elicited transient currents in a
moderate percentage of cells (approximately 25%).
Similar results were obtained by Mochizuki et al. [19],
who showed that the TRPV4 mRNA is uniquely abundant
among the TRP channels that reportedly exist in urinary
bladder epithelium. In an immunohistochemical study,
TRPV4 was localized in basal and intermediate urothelial
cell layers of mice bladders, and TRPV4 expression was
also confirmed in primary cell cultures. The functional
expression of TRPV4 in urothelial cells was evidenced
by using the selective agonist 4a-PDD in Ca
2+ imaging
experiments. Furthermore, the authors confirmed that in
vitro mechanical stretch stimulation of urothelial cells
activated TRPV4, leading to increased [Ca
2+]i and ATP
release. These findings were also presented elsewhere [20].
At the most recent annual meeting of the International
Continence Society (San Francisco, CA, USA, 29 Septem-
ber to 3 October 2009), several posters about the role of
TRPV4 channels in bladder physiology and their possible
involvement in bladder overactivity were presented.
Everaerts et al. [21] showed that 4a-phorbol-diesanoate
(APP441-1) (Figure 1), another specific agonist for
TRPV4 [22], induced an increase of [Ca
2+]i in urothelial
cells from wild-type mice but not in cells from TRPV4
knockout mice in vitro. In conscious rats, application of
APP441-1 induced a significant increase in voiding
pressure and decrease in the intercontractile interval. In
urethane anesthetized wild-type mice, APP441-1
induced bladder overactivity, characterized by a decrease
in the intercontractile interval, but did not induce any
effects in the TRPV4 knockout mice.
An evaluation of the functional expression of different
TRP channels (TRPA1, TRPV1, TRPV2, TRPV4, and
TRPM8) in mouse urothelial cells was reported by
Everaerts et al. [23]. Quantitative polymerase chain
reaction showed very low levels of TRPA1 and TRPV1
mRNA but high levels of TRPV4 and TRPV2 mRNA.
TRPM8 mRNA was not detected. Functional analysis
using Ca
2+ imaging showed that the majority of cultured
urothelial cells responded to 4a-PDD, indicating an
important functional role for TRPV4 in these cells.
Since TRPV4 channels are activated by mechanical
stretch, Janssen et al. [24] evaluated the co-localization
of these channels and adherence junctions (E-cadherin)
in the urothelium of the human kidney, ureter, and
bladder. A co-localization between TRPV4 and
E-cadherin was found throughout the urogenital tract.
The co-localization of TRPV4 and adherence junctions in
the urothelium of the bladder (as well as of the other
tissues) means that TRPV4 is connected to the rigid
structural network that includes the intracellular actin
cytoskeleton and extracellular anchoring cell junctions
and confirms that TRPV4 is involved in the sensation of
stretch in the urothelium of human bladder. The same
authors [25] reported that such a co-localization between
TRPV4 and E-cadherin was also seen in the urothelium of
normal mouse bladder but not in the TRPV4 knockout
mice.
Finally,Miyamoto et al. [26] showed that in patients with
benign prostatic hyperplasia or bladder outlet obstruc-
tion, bladder urothelium showed higher expressions of
TRPA1, TRPV4, and TRPV1, confirming that these
channels are candidates as mechanosensors in the
human urinary bladder and indicating that modulation
of these channels could be a novel therapy for overactive
bladder and storage dysfunction.
Future directions
The findings reported above indicate that TRPV4 is
stimulated during distension of the bladder urothelium
and could contribute to abnormal overactivity of the
bladder in pathological conditions. As reported by
Thorneloe et al. [15], nifedipine reversed GSK1016790A
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2+
channels in mediating TRPV4 contractions. In addition,
TRPV4 stimulation induces ATP release from the urothe-
lium [13,14], and it has been reported that intravesical
administration of ATP activates bladder afferent nerves
and in turn triggers bladder hyperactivity [27]. It will be
extremely interesting, therefore, to evaluate the effects of
antagonists of the TRPV4 receptor in different models of
bladder overactivity, although so far the activity of any
antagonist has not been reported in the literature.
The first report about small molecules showing selective
antagonistic activity in the human TRPV4 receptor
expressed in HEK-293 cells was a poster presented by
Hydra Biosciences, Inc. (Cambridge, MA, USA) at the
2008 meeting of the Society for Neuroscience [28].
More recently, Vincent et al. [29], by evaluating a library
of commercial compounds, showed that one of these,
namely RN-1734 (Figure 1), is endowed with TRPV4
antagonist properties. By using electrophysiology and
intracellular calcium influx in rat and mouse TRPV4
channels, these authors demonstrated that RN-1734
completely inhibited both ligand- and hypotonicity-
activated TRPV4. In addition, RN-1734 was found to be
selective for TRPV4 in a TRP selectivity panel including
TRPV1 and TRPV3. Furthermore, a recent patent from
GlaxoSmithKline (Uxbridge, Middlesex, UK) [30]
describes a series of diazabicyclo[2.2.1]hept-2-yl analogs
endowed with TRPV4 antagonistic properties for the
treatment or prevention of different diseases, including
overactive bladder (Figure 1).
It has previously been reported ([13,14] and references
therein) that in the urinary bladder, the closely related
TRPV1 channel is expressed in sensory nerve terminals,
in the epithelial cells (urothelium), and in interstitial
cells. This channel can be gated by the pungent vanilloid
compound capsaicin and also by a number of other
noxious stimuli, including intense heat (>43°C),
protons (pH <5), and certain lipid molecules, namely
anandamide, N-arachadonyl dopamine, and 5-hydro-
peroxyeicosatetraenoic acid [31].
Analysis of TRPV1 knockout mice indicated that TRPV1
participates in normal bladder function. Mice lacking
TRPV1 display a higher frequency of low-amplitude
nonvoiding bladder contractions in comparison with
wild-type animals. TRPV1 is required for bladder stretch
detection, which involves the stretch-evoked release of
ATP and nitric oxide. Accordingly, TRPV1 antagonists
increased the threshold for activation of the micturition
reflex in the anesthetized rat volume-induced micturi-
tion reflex model and also inhibited detrusor overactivity
induced by intravesical capsaicin and intravesical citric
acid [32]. Furthermore, patients suffering from neuro-
genic bladder hyperreactivity have experienced relief
from both urinary frequency and urgency after intrave-
sical desensitization with TRPV1 agonists [33,34]. How-
ever, a problem arising with the administration of TRPV1
blockers in animals is the induction of hyperthermia, an
effect observed in rats, mice, dogs, and monkeys [35].
At present, potent small-molecule TRPV1 antagonists are
undergoing clinical trials for chronic pain. Clinical
development of TRPV1 antagonists also demonstrated
that many drug candidates evoke a febrile reaction that
varies among patients, probably owing to the TRPV1 gene
polymorphism that might be a cause of the intersubject
variability in response to TRPV1 antagonists [36].
Whether or not TRPV1 involvement in thermoregulation
will impede clinical development of TRPV1 antagonists
is still an open question [35]. Although the character-
istics of TRPV1 and TRPV4 are quite different [1], this
aspect should be carefully taken into consideration.
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